Oxaliplatin (OXA) is a first-line agent in the systemic treatment of colorectal cancer (CRC).
OXA-induced neuropathy is the most prominent adverse effect, both during and after the …

Colorectal cancer represents a major health problem in the Western world. Many drugs have
been used for the treatment of this disease, but there is little information about how …

The use of gemcitabine and oxaliplatin is well documented in selected patients with
advanced biliary tract carcinoma (BTC), but little is known on the feasibility of systemic …

Introduction: Platinum-derived drugs are commonly used for the treatment of solid tumors.
The differences in chemical structures of these molecules lead to different pharmacological …

This paper describes a method for the determination of platinum derived from cisplatin in
human plasma ultrafiltrate using liquid chromatography tandem mass spectrometry (LC …

BACKGROUND: Oxaliplatin has less haematological toxicity than cisplatin and carboplatin.
The combination of pemetrexed, oxaliplatin and bevacizumab appeared well tolerated and …

Colorectal cancer is a common cancer in older patients with nearly 70% of all cases
diagnosed in patients 65 years and older. Many chemotherapy clinical trials that have …

Background/Aim: The effect of renal dysfunction on the toxicity and efficacy of oxaliplatin
remains unclear. We investigated the association between creatinine clearance (Ccr), a …

Dose adjustment based on renal function is essential in S-1, which contains the 5‑
fluorouracil prodrug tegafur, and platinum-based agent oxaliplatin (SOX) combination …

Background/Aim: Definitive chemoradiotherapy with cisplatin (CDDP) plus 5-fluorouracil is
the standard treatment for locally advanced esophageal squamous cell carcinoma (LA …